Portal de Periódicos da CAPES

Providing Appropriate Risk Information on Genome Editing for Patients

2016; Elsevier BV; Volume: 34; Issue: 2 Linguagem: Inglês

10.1016/j.tibtech.2015.12.002

0167-9430

Motoko Araki, Tetsuya Ishii,

Pluripotent Stem Cells Research

Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.